River Vision Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $475M

River Vision General Information

Description

Developer of protein therapies designed for the treatment of Graves' Orbitopathy. The company's protein therapies include a human monoclonal antibody Teprotumumab, is a fully human mAb inhibitor of insulin-like growth factor type 1 receptor (IGF-1R) used for the treatment of active phase Graves Orbitopathy (GO), enabling users treat patients with tissue proliferation and excess production of extracellular matrix.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • One Rockefeller Plaza
  • Suite 1204
  • New York, NY 10020
  • United States
+1 (212)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • One Rockefeller Plaza
  • Suite 1204
  • New York, NY 10020
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

River Vision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 08-May-2017 $475M Completed Product Development
2. Early Stage VC (Series B) 01-May-2017 Completed Generating Revenue
1. Early Stage VC (Series A) 21-Jan-2016 $27.1M $27.1M Completed Startup
To view River Vision’s complete valuation and funding history, request access »

River Vision Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view River Vision’s complete cap table history, request access »

River Vision Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lundbeckfonden BioCapital Venture Capital Minority
Narrow River Management Limited Partner Minority
SR One Corporate Venture Capital Minority
Vivo Capital Venture Capital Minority
To view River Vision’s complete investors history, request access »

River Vision FAQs

  • When was River Vision founded?

    River Vision was founded in 2011.

  • Where is River Vision headquartered?

    River Vision is headquartered in New York, NY.

  • What industry is River Vision in?

    River Vision’s primary industry is Biotechnology.

  • Is River Vision a private or public company?

    River Vision is a Private company.

  • What is the current valuation of River Vision?

    The current valuation of River Vision is .

  • What is River Vision’s current revenue?

    The current revenue for River Vision is .

  • How much funding has River Vision raised over time?

    River Vision has raised $27.1M.

  • Who are River Vision’s investors?

    Lundbeckfonden BioCapital, Narrow River Management, SR One, and Vivo Capital have invested in River Vision.

  • When was River Vision acquired?

    River Vision was acquired on 08-May-2017.

  • Who acquired River Vision?

    River Vision was acquired by Horizon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process